OCUL
OCULAR THERAPEUTIX, INC
$8.25
-6.25%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders9 funds
Inst. Value$580.3M
Inst. Activity7 buys / 1 sells
Insider Activity1B / 16S
Insider Net $-$1.7M
SEC Reports6
Press Releases3
Recent Activity
Jun 5, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocul
Jun 4, 2026
Press
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple dat
Impact 7/10
Jun 3, 2026
Insider
Waheed Nadia sold 14,828 shares
Chief Medical Officer @ $8.27 ($122.6K)
May 28, 2026
SEC
Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted open-market sales of
CLUSTER — Impact 3/10
May 28, 2026
Insider
Dugel Pravin sold 394,696 shares
See Remarks @ $0.00 ($0.00)
May 26, 2026
Insider
Kaiser Peter sold 2,967 shares
Chief Development Officer @ $8.20 ($24.3K)
May 5, 2026
SEC
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was belo
PRESS-RELEASE — Impact 6/10
May 5, 2026
SEC
Ocular Therapeutix reported Q1 2026 net revenue of $10.8M (up 0.8% YoY), essentially flat, and a net loss of -$0.40/shar
8-K — Impact 5/10
Price Targets
$26.00
+215.2% upside
Strong Buy
Current $8.25
Low $18.00
Median $27.00
High $34.00
11 analysts
$18.00
$34.00
Analyst Ratings
6Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| May 5, 2026 | Needham | REITERATE | Buy → Buy |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 3, 2026 | Clear Street | MAINTAIN | Buy → Buy |
| Feb 20, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-1.62 ▼ -15.9% | $-1.70 — $-1.55 | -14% YoY | 4 |
| Next FY | $-1.53 ▼ -21.7% | $-1.75 — $-1.25 | 6% YoY | 5 |
| Current Q | $-0.41 ▼ -21.5% | $-0.42 — $-0.38 | -4% YoY | 5 |
| Next Q | $-0.41 ▼ -15.8% | $-0.45 — $-0.38 | -9% YoY | 5 |
Latest Reports
BULLISH
Press
7/10
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple dat
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted open-market sales of
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was belo
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $385.9M | ADD |
| VANGUARD GROUP INC | $140.5M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $17.7M | ADD |
| MORGAN STANLEY | $10.7M | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $9.6M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Waheed Nadia | SELL | $122.6K |
| May 28, 2026 | Dugel Pravin | G | $0.00 |
| May 26, 2026 | Kaiser Peter | SELL | $24.3K |
| May 26, 2026 | Nayak Sanjay | SELL | $15.2K |
| May 26, 2026 | Heier Jeffrey | SELL | $24.7K |
9 institutional holders with $580.3M total value (47,801,901 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, CHARLES. Net buying activity: 7 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 31,785,605 | $385.9M | 66.5% | ADD +62.1% |
| 2 | VANGUARD GROUP INC | 11,575,193 | $140.5M | 24.2% | ADD +26.3% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,460,457 | $17.7M | 3.1% | ADD +29.9% |
| 4 | MORGAN STANLEY | 879,144 | $10.7M | 1.8% | TRIM -64.3% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 791,200 | $9.6M | 1.7% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 601,360 | $7.3M | 1.3% | ADD +34.5% |
| 7 | TWO SIGMA INVESTMENTS, LP | 380,713 | $4.6M | 0.8% | ADD +62.5% |
| 8 | WELLS FARGO & COMPANY/MN | 255,222 | $3.1M | 0.5% | ADD +95.0% |
| 9 | NORGES BANK | 73,007 | $886.3K | 0.2% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 9,163,240 | 11,575,193 | +26.3% | $140.5M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,124,103 | 1,460,457 | +29.9% | $17.7M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 2,465,676 | 879,144 | -64.3% | $10.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 791,200 | — | $9.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 447,116 | 601,360 | +34.5% | $7.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 234,213 | 380,713 | +62.5% | $4.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 130,852 | 255,222 | +95.0% | $3.1M | 2025-Q4 |
| NORGES BANK | NEW | — | 73,007 | — | $886.3K | 2025-Q4 |
| FMR LLC | ADD | 19,608,171 | 31,785,634 | +62.1% | $371.6M | 2025-Q3 |
| UBS Group AG | TRIM | 1,965,151 | 1,248,266 | -36.5% | $14.6M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 759,260 | 447,116 | -41.1% | $5.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 110,832 | 234,213 | +111.3% | $2.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 74,150 | 130,852 | +76.5% | $1.5M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 410,048 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | DOUBLED | 941,294 | 19,608,171 | +1983.1% | $182.0M | 2025-Q2 |
| UBS Group AG | ADD | 1,334,939 | 1,965,151 | +47.2% | $18.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 461,230 | 110,832 | -76.0% | $1.0M | 2025-Q2 |
| UBS Group AG | ADD | 876,546 | 1,334,939 | +52.3% | $9.8M | 2025-Q1 |
| FMR LLC | DOUBLED | 460,447 | 941,294 | +104.4% | $6.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 252,939 | 461,230 | +82.3% | $3.4M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 454,000 | — | $3.3M | 2025-Q1 |
| UBS Group AG | ADD | 684,776 | 876,546 | +28.0% | $7.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 456,426 | 74,208 | -83.7% | $633.7K | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,162,481 | 1,584,175 | +36.3% | $13.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,110,460 | — | $9.7M | 2024-Q3 |
7 unique insiders with 17 transactions. Net insider value: -$1.7M ($461.4K bought, $2.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Waheed Nadia | Chief Medical Officer | SELL | 14,828 | $8.27 | $122.6K |
| May 28, 2026 | Dugel Pravin | See Remarks | G | 394,696 | $0.00 | $0.00 |
| May 26, 2026 | Kaiser Peter | Chief Development Officer | SELL | 2,967 | $8.20 | $24.3K |
| May 26, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 1,858 | $8.20 | $15.2K |
| May 26, 2026 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 3,018 | $8.20 | $24.7K |
| May 26, 2026 | Dugel Pravin | See Remarks | SELL | 21,156 | $8.20 | $173.5K |
| Apr 9, 2026 | Dugel Pravin | See Remarks | G | 394,696 | $0.00 | $0.00 |
| Feb 23, 2026 | Dugel Pravin | See Remarks | SELL | 20,056 | $8.28 | $166.1K |
| Feb 23, 2026 | Kaiser Peter | Chief Development Officer | SELL | 2,810 | $8.28 | $23.3K |
| Feb 23, 2026 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 3,057 | $8.28 | $25.3K |
| Feb 23, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 1,759 | $8.28 | $14.6K |
| Feb 20, 2026 | Waheed Nadia | Chief Medical Officer | SELL | 3,510 | $7.74 | $27.2K |
| Feb 20, 2026 | LINDSTROM RICHARD L MD | Director | BUY | 60,229 | $7.66 | $461.4K |
| Feb 12, 2026 | Dugel Pravin | See Remarks | SELL | 124,882 | $9.04 | $1.1M |
| Feb 12, 2026 | Notman Donald | Chief Operating Officer | SELL | 11,446 | $9.04 | $103.5K |
| Feb 12, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 10,348 | $9.04 | $93.5K |
| Feb 12, 2026 | Waheed Nadia | Chief Medical Officer | SELL | 7,863 | $9.04 | $71.1K |
| Feb 4, 2026 | Notman Donald | Chief Operating Officer | SELL | 6,035 | $8.54 | $51.5K |
| Feb 2, 2026 | Notman Donald | Chief Operating Officer | SELL | 5,455 | $9.14 | $49.9K |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 3 mixed, 3 neutral. Avg impact: 4.7/10.
NEUTRAL
CLUSTER
3/10
Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenu
May 5, 2026
NEUTRAL
8-K
5/10
Ocular Therapeutix reported Q1 2026 net revenue of $10.8M (up 0.8% YoY), essentially flat, and a net
May 5, 2026
NEUTRAL
DEFA14A
3/10
Ocular Therapeutix filed a DEFA14A (definitive additional proxy soliciting materials) providing noti
Apr 30, 2026
MIXED
CLUSTER
5/10
A cluster of insider transactions at Ocular Therapeutix (OCUL) shows mixed activity: one significant
Feb 26, 2026
MIXED
CLUSTER
6/10
A cluster of insider transactions at Ocular Therapeutix (OCUL) over the past week shows mixed activi
Feb 26, 2026
BULLISH
7/10
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will
Jun 4, 2026
BULLISH
8/10
Ocular Therapeutix presented additional Week 52 post-hoc data from its SOL-1 Phase 3 trial for AXPAX
Apr 13, 2026
NEUTRAL
3/10
Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy
Apr 1, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 18 analysts: 6 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$26.00 mean target
+215.2% upside
Strong Buy (3.00)
$18.00 Low
$34.00 High
| Metric | Value |
|---|---|
| Current Price | $8.25 |
| Target Low | $18.00 |
| Target Mean | $26.00 |
| Target Median | $27.00 |
| Target High | $34.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$-1.62 | $-1.70 | $-1.55 | -14.0% | -15.9% | 0↑ 1↓ | $0.1B | -0.2% | 4 |
| Next FY 2027-12-31 |
$-1.53 | $-1.75 | $-1.25 | 5.7% | -21.7% | 0↑ 2↓ | $0.1B | 123.9% | 5 |
| Current Q 2026-06-30 |
$-0.41 | $-0.42 | $-0.38 | -4.3% | -21.5% | 0↑ 1↓ | $0.0B | -1.9% | 5 |
| Next Q 2026-09-30 |
$-0.41 | $-0.45 | $-0.38 | -8.9% | -15.8% | 0↑ 1↓ | $0.0B | -3.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.410 | |
| 7d ago | $-0.338 | -0.072 |
| 30d ago | $-0.338 | -0.072 |
| 60d ago | $-0.338 | -0.072 |
| 90d ago | $-0.380 | -0.030 |
12 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| May 5, 2026 | Needham | REITERATE | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 3, 2026 | Clear Street | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 8, 2025 | Needham | REITERATE | Buy | Buy |
| Dec 8, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 25, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 5, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Oct 30, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Oct 8, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 3, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Oct 3, 2025 | Baird | MAINTAIN | Outperform | Outperform |
| Oct 2, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Oct 1, 2025 | Needham | MAINTAIN | Buy | Buy |
| Oct 1, 2025 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Sep 15, 2025 | Chardan Capital | INITIATE | — | Buy |
| Aug 6, 2025 | Scotiabank | MAINTAIN | Sector Outperform | Sector Outperform |
| Aug 5, 2025 | Needham | MAINTAIN | Buy | Buy |
| May 29, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 6, 2025 | Needham | MAINTAIN | Buy | Buy |
| Apr 8, 2025 | William Blair | INITIATE | — | Outperform |
| Apr 8, 2025 | Needham | REITERATE | Buy | Buy |
| Mar 18, 2025 | RBC Capital | INITIATE | — | Outperform |
| Mar 11, 2025 | Needham | INITIATE | — | Buy |
| Mar 4, 2025 | Citizens Capital Markets | MAINTAIN | Market Outperform | Market Outperform |
| Mar 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 16, 2024 | Scotiabank | INITIATE | — | Sector Outperform |
| Oct 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 8, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Aug 1, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 21, 2024 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jun 20, 2024 | TD Cowen | UPGRADE | Hold | Buy |
| Jun 14, 2024 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jun 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 8, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| May 8, 2024 | TD Cowen | MAINTAIN | Hold | Hold |
| Apr 19, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 16, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Mar 13, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Mar 13, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 12, 2024 | TD Cowen | MAINTAIN | Market Perform | Market Perform |
| Mar 12, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Feb 26, 2024 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceut
Jun 4, 2026
fda
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
<p>BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company comm
Jun 1, 2026
short_volume
Short Volume: OCUL — 61.8% short (0.5M / 0.9M)
Short: 540,515 | Exempt: 0 | TRF Vol: 873,993 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated b
May 15, 2026
short_volume
Short Volume: OCUL — 57.0% short (0.5M / 0.9M)
Short: 537,718 | Exempt: 672 | TRF Vol: 943,231 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 8, 2026
activist
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated b
May 5, 2026
earnings
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
<p align="center"><em>Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R</
May 5, 2026
earnings_calendar
OCUL Q1 2026 Earnings After Market Close — 2026-05-05
May 4, 2026
earnings_calendar
OCUL Q1 2026 Earnings After Market Close — 2026-05-04
May 1, 2026
short_volume
Short Volume: OCUL — 58.7% short (0.6M / 1.0M)
Short: 559,182 | Exempt: 500 | TRF Vol: 952,906 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: OCUL — 64.6% short (0.6M / 0.9M)
Short: 581,457 | Exempt: 1,066 | TRF Vol: 900,672 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
other
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 <pre>Ocular’
Apr 14, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceu
Apr 13, 2026
fda
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
<p align="center"><em>New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control<
Apr 1, 2026
fda
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
<p>BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company com